(USD M) | Mar'20 | Jun'20 | Sep'20 | Dec'20 | Mar'21 | Jun'21 | Sep'21 | Dec'21 | Mar'22 | Jun'22 | Sep'22 | Dec'22 | Mar'23 | Jun'23 | Sep'23 | Dec'23 | Mar'24 | Jun'24 | Sep'24 | Dec'24 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LTM Revenue % growth | 1,887.9 8.2% | 1,945.4 10.1% | 2,037.3 13.7% | 2,146.9 16.7% | 2,326.1 23.2% | 2,522.5 29.7% | 2,681.0 31.6% | 2,831.6 31.9% | 2,880.9 23.9% | 2,928.6 16.1% | 2,909.0 8.5% | 2,886.9 2.0% | 2,883.5 0.1% | 2,866.0 (2.1%) | 2,926.5 0.6% | 2,949.8 2.2% | 2,928.6 1.6% | 2,876.8 0.4% | 2,876.3 (1.7%) | 2,893.1 (1.9%) |
LTM NOPAT % growth | 255.0 N/A | 277.5 8.8% | 299.3 7.9% | 333.4 11.4% | 407.5 22.2% | 499.1 22.5% | 590.7 18.3% | 644.6 9.1% | 666.1 3.3% | 671.1 0.8% | 619.9 (7.6%) | 545.2 (12.1%) | 509.5 (6.6%) | 473.5 (7.1%) | 504.9 6.6% | 557.6 10.4% | 532.5 (4.5%) | 492.9 (7.5%) | 472.9 (4.0%) | 469.0 (0.8%) |
Discount rate | 5.2% | 5.2% | 5.2% | 5.5% | 6.3% | 6.0% | 6.1% | 6.1% | 6.9% | 7.6% | 8.2% | 8.4% | 8.1% | 8.4% | 9.1% | 8.4% | 8.7% | 8.9% | 8.3% | 9.1% |
Earnings Power Value (EPV) | 4,934.0 | 5,382.3 | 5,759.0 | 6,100.5 | 6,517.0 | 8,268.1 | 9,671.8 | 10,595.6 | 9,657.1 | 8,819.7 | 7,525.9 | 6,520.5 | 6,314.7 | 5,652.8 | 5,543.0 | 6,634.5 | 6,104.1 | 5,558.2 | 5,728.8 | 5,182.0 |
Enterprise Value (EV) | 11,118.6 | 16,247.0 | 20,113.5 | 20,531.6 | 20,289.6 | 26,487.1 | 31,794.1 | 34,750.5 | 30,671.9 | 21,957.6 | 18,318.8 | 17,094.2 | 24,834.4 | 27,465.9 | 27,409.3 | 25,516.8 | 28,557.5 | 23,915.0 | 22,570.8 | 23,752.0 |
Market-Implied Value of Growth (MIVoG) | 6,184.6 | 10,864.7 | 14,354.5 | 14,431.0 | 13,772.6 | 18,219.0 | 22,122.3 | 24,154.9 | 21,014.8 | 13,137.9 | 10,792.8 | 10,573.8 | 18,519.7 | 21,813.2 | 21,866.3 | 18,882.3 | 22,453.3 | 18,356.8 | 16,842.0 | 18,570.0 |
EPV as % of EV | 44.4% | 33.1% | 28.6% | 29.7% | 32.1% | 31.2% | 30.4% | 30.5% | 31.5% | 40.2% | 41.1% | 38.1% | 25.4% | 20.6% | 20.2% | 26.0% | 21.4% | 23.2% | 25.4% | 21.8% |
MIVoG as % of EV | 55.6% | 66.9% | 71.4% | 70.3% | 67.9% | 68.8% | 69.6% | 69.5% | 68.5% | 59.8% | 58.9% | 61.9% | 74.6% | 79.4% | 79.8% | 74.0% | 78.6% | 76.8% | 74.6% | 78.2% |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of Dec 31, 2024, West Pharmaceutical Services, Inc.'s Earnings Power Value is approximately $5,182.0M.
As of Dec 31, 2024, West Pharmaceutical Services, Inc.'s Enterprise Value (EV) estimates at $23.8B.
As of Dec 31, 2024, West Pharmaceutical Services, Inc.'s Net operating profit after tax (NOPAT) is approximately $469.0M.